Search results
Is Pfizer Stock Fully Valued At $28?
Forbes· 19 hours agoPfizer (NYSE: PFE) reported its Q1 results last week, with revenues and earnings beating the street estimates.
Cramer explains how to maintain a 'balanced' portfolio as the economy slows
CNBC· 1 hour agoCNBC's Jim Cramer on Tuesday said Wall Street is currently going through a tricky stage of the...
Pfizer reports patient death in Duchenne gene therapy study
Reuters· 3 hours ago, opens new tab experimental gene therapy for a muscle-wasting disorder called Duchenne muscular...
Pfizer (PFE) Q1 Earnings and Revenues Beat Estimates
Zacks via Yahoo Finance· 7 days agoPfizer (PFE) delivered earnings and revenue surprises of 46.43% and 7.37%, respectively, for the quarter ended March 2024. Do the numbers hold clues to...
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Zacks via Yahoo Finance· 1 day agoPfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to...
Pfizer Is Adding a Wall Street Analyst to Its C-Suite. What He Thinks the Company Needs to Do.
Barrons.com· 1 day agoSTOCK ALERT Andrew Baum, the prominent Wall Street drug company analyst, has never been much of a...
Leerink Partnrs Comments on Pfizer Inc.’s Q2 2024 Earnings (NYSE:PFE)
ETF DAILY NEWS· 22 hours agoPfizer Inc. (NYSE:PFE – Free Report) – Stock analysts at Leerink Partnrs upped their Q2 2024 earnings estimates for Pfizer in a report issued on Thursday ...
Pfizer hires Citi healthcare analyst Baum to lead strategy and innovation
Seeking Alpha· 1 day agoPfizer appoints Andrew Baum from Citi as chief strategy and innovation officer, responsible for...
Pfizer's Options Frenzy: What You Need to Know - Pfizer (NYSE:PFE)
Benzinga· 1 day agoLoading... Loading... Deep-pocketed investors have adopted a bullish approach towards Pfizer PFE , and it's something market players shouldn't ignore. Our tracking of public ...
Pfizer's Stock Is a Buy. Here Are Six Reasons Why.
Motley Fool via Yahoo Finance· 6 days agoPfizer (NYSE: PFE) stock is an investing enigma. The drugmaker's shares have printed fresh 52-week lows consistently over the past two years, putting its...